Onconova Therapeutics Inc

NASDAQ:ONTX   3:59:35 PM EDT
0.60
-0.02 (-3.00%)
Products

Onconova Therapeutics Announces FDA Permission For Study To Proceed Under Its Investigational New Drug Application For Multi-Kinase Cdk4/6 Inhibitor On 123300

Published: 12/21/2020 16:26 GMT
Onconova Therapeutics Inc (ONTX) - Onconova Therapeutics Announces FDA Permission for Study to Proceed Under Its Investigational New Drug Application for Multi-kinase Cdk4/6 Inhibitor on 123300.
Onconova Therapeutics Inc - First Patient Will Be Enrolled During First Half of 2021 for Phase 1 Trial With on 123300.